The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | Practical considerations for molecular profiling in NSCLC
Pilar Garrido Lopez, MD, PhD, University Hospital Ramón y Cajal, Madrid, Spain, comments on the value of molecular profiling in patients with non-small cell lung cancer (NSCLC) as a way of differentiating their specific tumor type, and therefore offering targeted therapies from the range presently available. Such agents would be of particular value in the second-line setting, and within the field of lung cancer, one of the most significant challenges at present is the difficulty of obtaining a large enough sample to fulfil next-generation sequencing (NGS) requirements. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
